TOP HEADLINES

Featured Story

McDonald's ditches antibiotics-raised chicken as legislators launch bill to curb use

Fast-food giant McDonald's announced Wednesday that it will phase out all chicken raised with antibiotics used in human healthcare within the next two years. The policy is part of the company's new Global Vision for Antimicrobial Stewardship in Food Animals, according to a statement from the company.

Cats and Febreze may hold key to treating devastating Niemann-Pick disease

A new study shows that cats with naturally occurring Niemann-Pick type C--which is nearly identical to the human form of the disease--are greatly helped by the active ingredient in the odor-fighting household spray Febreze.

Akorn hits new high on strong earnings and fast-growing animal health venture

Shares of generic drug maker Akorn ($AKRX) shot up 14% late last week to $55.86, after the company announced on Thursday strong preliminary 2014 results and expectations of 2015 year-over-year revenue growth of 47% and earnings-per-share growth of 62%.

Purina faces lawsuit over dogs allegedly sickened by Beneful

A lawsuit filed by an angry dog owner against Nestle Purina PetCare alleges that the company's popular dog food, Beneful, has sparked more than 3,000 online complaints claiming that the product has sickened their dogs.

Brain cancer therapy pioneered in dogs wins NCI grant for human development

Dogs with spontaneously occurring, highly aggressive brain tumors such as glioblastoma multiforme have proven to be highly accurate models of human brain cancer. So when the owners of a 12-year-old mixed-breed dog with glioblastoma showed up at the Virginia-Maryland Regional College of Veterinary Medicine having exhausted all other treatment options, they agreed to try an experimental technology called nonthermal irreversible electroporation.

MORE NEWS

From Our Sister Sites

FierceBiotech

Merck has pulled the plug on Cubist Pharmaceuticals' early R&D operation, cutting 120 jobs in Massachusetts as it integrates its latest big acquisition.

FierceBiotech

Milan-based Genenta Science has raised $11 million for its work on a new gene therapy. According to a brief release, the biotech says that Banca Esperia, the private bank of Mediobanca and Mediolanum, supported the A round.